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he Epstein-Barr virus (EBV; human herpesvi-
rus 4, HHV-4) is the first human virus identi-
fied with a proven association with the
pathogenesis of cancer. It belongs to the Herpesvir-
idae family, subfamily Gammaherpesvirinae, genus Lym-
phocryptovirus.1 Although the Herpesviridae family
consists of more than 100 different viruses, it has
been demonstrated so far that only the following of
them are pathogenic for humans: herpes simplex
virus 1 (HSV-1; also known as human herpesvirus 1,
HHV-1), herpes simplex virus 2 (HSV-2; also known
as human herpesvirus 2, HHV-2), varicella zoster
virus (VZV; also known as human herpesvirus 3,
HHV-3), cytomegalovirus (CMV; also known as
human herpesvirus 5, HHV-5), human herpesvirus
6 (HHV-6), human herpesvirus 7 (HHV-7), Kaposi
sarcoma–associated herpesvirus (KSHV; also known
as human herpesvirus 8, HHV-8) and, as discussed
here, EBV.2- see front matter
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CONTEXT OF PROLIFERATIVE
HEMATOLOGICAL DISEASES
EBV can infect both B cells and epithelial cells,
and transient reactivation of infection and viral
replication in epithelial cells of the nasopharynx
allows its spread in the body and latent infection of
B lymphocytes.3,4
In order to maintain the integrity of the viral
genome and to “get out” of the control of the host
immune system, in the phase of the latent infection
EBV shows the expression of several genes, includ-
ing genes for six EBV nuclear antigens (EBNA-1, -2,
-3A , -3B, and 3C, and EBV nuclear antigen–leader
protein, EBNA-LP), three EBV latent membrane
proteins (LMP-1, -2A, and -2B), two short non-
coding RNAs (EBV-encoded small RNA, EBER-1 and
-2), and BamHI-A rightward transcripts (BART).3–6
The different patterns of expression of the men-
tioned latent genes determine the occurrence of
different types of latency in the pathogenesis of
particular cancers.7
In type I latency EBNA-1 expression dominates; it
is observed in the course of Burkitt lymphoma (BL)
and stomach cancer.8–10 Type II latency is charac-
terized by the expression of latent genes EBNA-1 and
LMP-1 and LMP-2. It occurs in the course of Hodgkin
lymphoma (HL), nasopharyngeal carcinoma (NPC),
and in the state of heavy hyperinflammation in the
form of hemophagocytic lymphohistiocytosis.5,11–13291
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antigens is seen. This type of latency occurs in the
course of post-transplant lymphoproliferative disor-
ders (PTLD) associated with EBV infection, in AIDS-
related lymphomas, and in lymphoblastoid cell lines
(LCL).6,7,14 In vitro, EBV can infect primary B cells,
which are transformed into continuously proliferat-
ing LCL. It has been shown that in this process four
latent viral antigens, EBNA-2, -3A, and -3C and LMP-1,
are necessary.
One of the most important features of EBV is its
ability to infect various cell types, and the variety of
consequent diseases.15 It has been shown that in
human EBVs, infection may lead to the development
of a variety of cancers, including those derived from
hematopoietic and epithelial cells. Carcinogenesis
occurs mostly in transplant patients and in patients
with AIDS.16,17 Although cases of T-cell and epithe-
lial cell infection have been documented, EBV is
characterized mainly by tropism for B lymphocytes;
under certain conditions their infection may result in
transformation to B-cell lymphoma.18
Due to the preferential infection of B cells,
the most common forms of EBV-associated lympho-
proliferative disorders are B-cell lymphomas: HL,
non-Hodgkin lymphomas (NHLs), including BL and
diffuse large B-cell lymphoma (DLBCL).18–21 PTLD
also develops as a result of EBV infection. Due to the
still lengthening list of human cancers resulting from
EBV infection, in 1997 the World Health Organiza-
tion (WHO) classified EBV as a tumor virus.22
The function of latent EBV antigens has been and
still is the subject of intense research since an
undeniable link between the incidence of lympho-
proliferative disorders developing after EBV infec-
tion and the presence of latent viral infection has
been noticed. Information on the life cycle of EBV,
its gene expression regulation and molecular mech-
anisms of malignant transformation may be essential
for a complete understanding of the role of this viral
infection in the course of a number of lymphopro-
liferative diseases and to develop new methods of
treatment. According to current knowledge, latent
antigens encoded by EBV interfere with a number of
important cellular pathways, thereby leading to
tumorigenesis.6,23,24
The main biological functions of latent proteins
are summarized in Table 1.THE ROLE OF LATENT ANTIGENS IN
LYMPHOCYTE TRANSFORMATION
EBNA-1 is required for replication and mainte-
nance of EBV episomes in dividing host cells. This
protein is the only EBV-encoded antigen whose
constitutive expression is found in all cancersassociated with infection by the virus.25,26 EBNA-1
has two main functional domains: the C-terminal
domain binding viral DNA and the N-terminal
domain tethering to the genetic material of the host
cell.27 Increasing evidence indicates that EBNA-1
plays a role in the progression of human tumors
resulting from EBV infection. For example, reduction
of EBNA-1 expression by RNA interference results in
a reduction of proliferation and survival rates of a
number of EBV-positive tumor cells.28,29 These
observations are confirmed by the fact that the
increased expression of a dominant negative mutant
variant of EBNA-1 is associated with enhanced EBV-
positive BL cell death. This may indicate the anti-
apoptotic effect of EBNA-1.28,30 EBNA-1 expression
also is associated with increased risk of metastasis in
mice in which the tumor suppressor protein
Nm23–1H function has been blocked.31 An anti-
apoptotic effect of EBNA-1 also can be a conse-
quence of the interaction of the protein with
herpesvirus-associated ubiquitin-specific protease
(HAUSP), present in the host cell.32 In response to
DNA damage, HAUSP interacts with p53, causing its
stabilization. However, in cells infected by EBV,
EBNA-1 can effectively block the interaction
between HAUSP and p53, which results in degrada-
tion of the latter, controlled by the ubiquitin-
proteasome system.32 In addition, this protein can
damage promyelocytic leukemia bodies (PML) in
NPC cells and lead to genomic instability by "switch-
ing on" recombination activating genes RAG-1 and
RAG-2.26,33 Although for a long time it was thought
that cells expressing EBNA-1 are able to evade the
cellular response of the immune system due to
blockage of the presentation of antigens by major
histocompatibility complex (MHC) class I molecules,
it recently has been shown that the EBNA-1 protein
can be displayed to both CD4þ and CD8þ T lym-
phocytes. This creates the possibility of using this
protein as a potential target for immunotherapy of
cancers developing as a result of EBV infection.3,34,35
EBNA-2 plays a key role in immortalization of the
host cells, controlled by the EBV, coordinating the
level of transcription of the viral genes and several
cellular genes.13 EBNA-2 alters the activity of the
host cell genes, including genes encoding the B-cell
activation markers CD21 and CD23, and the tran-
scription factors.36,37 Based on the significant differ-
ences in the sequence, two serologically different
EBNA-2 proteins were identified, specific to type
1 and 2 EBV. This structural diversity is also reflected
in the EBNA-2 impact on B-cell transformation
in vitro.4 Although in vitro studies have shown that
EBNA-2 is essential for the initial stages of the
transformation of EBV-infected B lymphocytes, its
expression may be less important during tumor
progression. Observations made on the majority of
Table 1. Function of Latent EBV Antigens and Lymphomas Developing as a Consequence of Their Action
Latent
Protein
Function Developing Lymphoma Latency
Type
EBNA-1 Necessary for immortalization of B lymphocytes, involved in the EBV
genome replication and segregation of viral episomes during mitosis,
blocks the interaction between HAUSP and p53, facilitating p53
degradation
 BL
 HL
 AIDS-associated lymphomas
I, II, III
EBNA-2 Transcriptional co-activator enhancing expression of viral and host genes,
necessary for B-cell immortalization
 AIDS-associated lymphomas III
EBNA-3A Necessary for B-cell immortalization, interacts with the RBP-Jk, regulates
the Notch signaling pathway
 AIDS-associated lymphomas III
EBNA-3B Not necessary for B-cell immortalization, interacts with the RBP-Jk  AIDS-associated lymphomas III
EBNA-3C Necessary for B-cell immortalization, induces disturbances of various cell-
cycle checkpoints, interacts with the RBP-Jk, activates LMP, blocks p53-
dependent apoptosis, enhances the activity of the kinases in the
complex of cyclin D1/CDK6 and cyclin A/CDK2, induces degradation of
p27KIP1 and pRb, stabilizes c-Myc, cyclin D1 and Mdm2, affects
chromatin remodeling processes in the host cells
 AIDS-associated lymphomas III
EBNA-LP Interacts with EBNA-2 to inactivate p53 and pRb, interacts with
transcription factors of Notch pathway, contributes to immortalization
of B cells
 AIDS-associated lymphomas III
LMP-1 Mimics the signal associated with CD40 ligand binding, stimulates the
expression of bcl-2 and a20 to block apoptosis, acts as a constitutively
activated receptor stimulating many genes of the host cell, regulates
signaling pathways NF-kB, JAK/STAT, ERK, MAPK, IRF and Wnt
necessary for immortalization of B lymphocytes
 HL
 AIDS-associated lymphomas
 EBVþ DLBCL of the elderly
 DLBCL associated with chronic
inﬂammation
 Primary effusion lymphoma
 Lymphomatoid granulomatosis
II, III
LMP-
2ALMP-2B
Leads to EBV infection latency, LMP-2A blocks BCR signaling pathway,
and LMP-2B supports its action in this area
 HL
 AIDS-associated lymphomas
II, III
EBERs They form complexes with La and L22, interact with PKR, induce the
synthesis of interferon (IFN) and IL-10, bind with RIG-1 to activate type I
IFN; not essential for immortalization of B lymphocytes
 BL
 HL
 AIDS-associated lymphomas
 Systemic EBVþ T-cell LPD of
childhood
 EBVþ DLBCL of the elderly
I, II, III
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Table 1. (continued)
Latent
Protein
Function Developing Lymphoma Latency
Type
 DLBCL associated with chronic
inﬂammation
 Primary effusion lymphoma
 Lymphomatoid granulomatosis
 Angioimmunoblastic T-cell
lymphoma
 Extranodal NK/T-cell lymphoma,
nasal type
 Hydroa vacciniforme-like
lymphoma
 Systemic EBVþ T-cell
lymphoproliferative disorder of
childhood
BARFs Their protein products may modify the Notch signaling pathway; not
required for immortalization of B lymphocytes
 BL
 HL
 AIDS-associated
lymphomas
I, II, III
Data from Saha et al, 2011.6
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Epstein-Barr virus–associated lymphomas 295cancers resulting from EBV infection, with the
exception of those occurring in immunocompro-
mised patients, confirm this thesis.3,38,39
Genes encoding EBNA-3 (-3A, -3B, and -3C) are
present in the EBV genome in tandem sequences.40
EBNA-3 proteins of EBV type-1 and -2 have more
than 70% sequence homology.3 Genetic studies have
shown that while EBNA-3B is not required, -3A and
-3C are absolutely necessary for the transformation
of B cells, just like EBNA-2 and LMP-1.40,41 All three
EBNA-3 proteins affect the overall level of transcrip-
tional activity, including expression pattern of viral
genes and certain genes of the host cell during the
immortalization of the latter.40 EBNA-3A, together
with EBNA-3C, facilitates the LCL proliferation by
epigenetic repression of gene expression of pro-
apoptotic protein Bim, and cell cycle inhibitors.40,42
EBNA-3C increases cellular expression of CD21 and
c-myc, enhances upregulation of LMP-1 expression
stimulated by EBNA-2, and reduces Cp promoter
activity.43,44 Besides being involved in transcrip-
tional regulation, EBNA-3A and -3C also play an
important role in cell cycle regulation.23,45–47
The expression of EBNA-LP (also known as EBNA-
5) is observed in parallel with the EBNA-2 expression
in infected naive B lymphocytes.48 Although the
results of several studies suggest that EBNA-LP plays
an important role in the transformation of B cells
that are responsible for co-activation of transcrip-
tional activity of the viral LMP-1 protein, controlled
by EBNA-2, the exact mechanism of action of this
antigen has still not been elucidated.4 EBNA-LP is a
typical viral protein consisting of 22- and 44-amino
acid variable regions encoded by two exons (W1 and
W2) located in the internal repeat-1 region (IR-1).
Moreover, EBNA-LP has a unique 45-residue C-termi-
nus encoded by exons Y1 and Y2. Due to the
presence of specific repeats in the viral genome
and alternative splicing, the latter give rise to a
number of proteins synthesized during the early
stage of viral infection.3,4 In vitro, transformed LCL
shows expression of few EBNA-LP isoforms. The fact
that in the majority of EBV-associated malignancies
EBNA-LP protein expression level is relatively low
requires further study.48 Although EBNA-LP does not
seem to be necessary for neoplastic transformation,
the results of the study suggest that it may play a role
in this process, influencing the course of a number
of important changes occurring in infected cells.
LMP-1 is an integral membrane protein encoded
by three exons. It is composed of six hydrophobic
membrane domains and a C-terminal cytoplasmic
fragment.3,49 It has been proven that for membrane
aggregation, necessary for B-cell immortalization, the
conservative N-terminal LMP-1 fragment and the first
two transmembrane domains are responsible.3 It has
been shown that LMP-1 expression results inmalignant transformation of rodent fibroblasts, caus-
ing their changes, which usually accompany primary
infection and B-cell transformation. Furthermore,
expression of LMP-1 in B cells results in blocking
of their apoptosis controlled by p53, in association
with transactivation of the anti-apoptotic factors bcl-
2 and A20.50 LMP-1 upregulates the expression of
interleukin-10 (IL-10), which stimulates B-cell prolif-
eration and reduces the intensity of the immune
response.51 LMP-1 also enhances proliferation of the
host cells, mimicking control by the CD40 nuclear
factor kappa B (NF-kB) signaling pathway and inter-
acting with factors associated with tumor necrosis
factor receptor (TNFR): TNFR-associated factor
(TRAF) and TNFR type 1–associated death domain
protein (TRADD).52 Interaction of LMP-1 with TRAF-
1 and -3 leads to increased expression of a number of
B-cell activation markers, including CD23, CD39,
CD40, CD44, and human leukocyte antigen (HLA)
class II, and adhesion molecules LFA-1 (lymphocyte
function-associated antigen 1) and ICAM-1 (intercel-
lular adhesion molecule 1).53 LMP-1 also may affect
the biogenesis of cytokines and their receptors,
resulting in further changes in the course of angio-
genesis and inflammatory response processes, con-
tributing to immune escape and development of
cancer.12,54
The LMP-2 gene encodes two isoforms of hydro-
phobic integral membrane protein-2A and LMP-2B,
which originate from two different promoters due to
EBV genome circularization. In contrast to LMP-2B,
LMP-2A contains an additional 118-residual cytoplas-
mic N-terminal domain encoded by exon 1. It
interacts with cellular tyrosine kinases Lyn and Syk
(spleen tyrosine kinase), blocking signal transduc-
tion via the B-cell receptor (BCR) and preventing
induction of the lytic cycle.55,56 Although LMP-2 is
not necessary to transform B cells, it was shown that
its presence is necessary to maintain the viral
episome for a long time, as it provides a temporary
enhancement of signal that promotes the survival of
B cells in lymphoid organs.57 It seems that LMP-2A
plays a central role in the course of chronic infection
of B lymphocytes. According to recent data, LMP-2B
affects regulation of signal transduction via BCR
controlled by LMP-2A, stimulating latently infected
B lymphocytes for reactivation.58
Of the two EBV-noncoding small RNAs (EBERs),
EBER-1shows a stronger expression. However, in
some situations the elevated expression of EBER-2
also is seen.59–61 In addition, they block apoptosis,
inhibit the antiviral activity of interferons (IFN)-alpha
and -gamma, and induce the production of IL-10. It
also has been shown that EBERs bind RIG-I (retinoic
acid-inducible gene) and activate its signaling path-
way, leading to the activation of type I IFN.62 EBERs
can also stimulate synthesis of IL-10 by NF-kB
E. Grywalska and J. Rolinski296independent activation of interferon regulatory fac-
tor 3 (IRF3) in BL cells. Although it was initially
suggested that EBERs are not necessary for the
occurrence of EBV-associated malignant transforma-
tion, it appears that they may be involved in tumor
progression through modulation of the signal trans-
duction in the immune system of the host.63
EBV is the first human virus for which a coding of
RNA micromolecules associated with lytic (BamHI
fragment H rightward open reading frame 1, BHRF1)
and latent genome areas (BamHI-A region rightward
transcript, BART) has been demonstrated.25
BARTs are encoded in the region of Bam H1A of
viral episome.64 Although the function of most
BARTs is still under investigation, their presence in
infected B cells in many lymphomas that developed
as a consequence of EBV infection suggests that they
may play an important role in their pathogenesis.CHARACTERISTICS OF LYMPHOMAS WITH
ESTABLISHED ASSOCIATION WITH EBV
INFECTION
Hodgkin Lymphoma
Epidemiologic links between EBV infection and
HL have been observed since discovery of this virus
in 1964,65 but the presence of this pathogen in
Hodgkin/Reed-Sternberg (HRS) cells was docu-
mented by Weiss et al66 no earlier than the 1980s.
The EBV-infected HRS cells show expression of
EBER, EBNA-1, LMP-1, and LMP-2A.67 The expression
of EBER was confirmed by means of in situ hybrid-
ization.68 HRS cells are most often found in HL
patients below 10 years of age (40%–85% of all the
cases) as well as in the patients older than 75 years
(45%–80%).69
Not all subtypes of classic HL harbor EBV to the
same degree.4,70 There are also data suggesting
that EBV is rarely associated with nodular
lymphocyte-predominant HL, while it is more com-
monly associated with mixed-cellularity HL and
lymphocyte-depleted HL (especially in patients
under 14 years of age and between 40–54 years of
age), whose EBV-positive rates are 75% and 95%,
respectively.4,69 In contrast, EBV is infrequently
found in nodular-sclerosis HL (15%–20%) and never
seen in lymphocyte-rich HL, and these two subtypes
have a better overall prognosis than others accord-
ingly. Therefore, EBV infection is closely related to
prognosis of CHL. A Scandinavian cohort study
showed that mononucleosis is associated with 2.5-
fold greater risk of HL, especially its EBVþ form.71
Markedly more frequent occurrence of EBVþ HL
in children and older persons may result from
primary infection with this virus and from the loss
of immunological control over latent infection,respectively. A small fraction of EBVþ HL cases
diagnosed in young adults may be in turn a conse-
quence of delayed primary EBV infection. Also a role
of genetic susceptibility was postulated in EBVþ HL
etiopathogenesis, as a relationship between the
presence of certain polymorphism in the HLA class
I region and incidence of mononucleosis and EBVþ
HL was documented.72 Therapy for both EBVþ and
EBV cases of HL is currently identical and results in
long term remissions in most patients, but relapsed
EBVþ patients have a poor prognosis.70Burkitt Lymphoma
There are two forms of BL: endemic and sporadic.
BL is an aggressive NHL characterized by the fastest
doubling time among human tumors. This neoplasm
is diagnosed mostly in children, more frequently in
boys than in girls. EBV infection is involved in as
many as 98% of the endemic BL cases diagnosed in
Africa. The endemic form of BLwas observed south
of the Sahara desert and in Papua New Guinea.73 The
incidence of this lymphoma is traditionally attributed
to co-factors causing suppression of T lymphocytes,
among them malaria, which is highly prevalent in
the abovementioned regions.74 The sporadic form of
the disease (observed outside Equatorial Africa and
Papua New Guinea) is diagnosed mostly in children
and adolescents (where it represents 50% of all
pediatric lymphomas); BL corresponds to 1%–2% of
all NHLs present in adult patients, including 15%–
20% of cases associated with EBV infection.25 The
incidence of BL in Europe amounts to approximately
0.2 cases per 100 000, and is two- to threefold higher
in men than in women. Although median age at
diagnosis of BL is 30 years, patients older than 40
years correspond to about 60% of the affected adults.
BL is an AIDS-defining illness, and its incidence
among HIV carriers is 10- to 100-fold higher than
that of sporadic cases. The association with EBV
infection was documented in 30%–40% of the BL
cases.75 Beginning at its early stages, the condition is
associated with clonal proliferation of lymphocytes.
EBV infection is most likely reflected by increased
proliferation rate, promoting development of critical
genetic rearrangements. One of the characteristic
chromosomal aberrations is translocation of proto-
oncogene c-MYC between chromosomes 8 and 14,
into one of the three immunoglobulin light-chain
loci. This results in constitutive expression of c-MYC
protein, a transcription factor associated with cellu-
lar proliferation and determining G1 to S phase
transition.76 Furthermore, this translocation tran-
scription of viral antigens other than non-
immunogenic EBNA1; the latter protein has a sepa-
rate promoter, independent from those of other viral
proteins.8 As a result of the abovementioned
Epstein-Barr virus–associated lymphomas 297alterations, the cells proliferate, become non-
immunogenic to cytotoxic T lymphocytes and prone
to further mutations.
Diffuse Large B-Cell Lymphomas
According to the 2008 WHO classification,
DLBCLs constitute a large heterogeneous group of
hematologic neoplasms, including a number of sep-
arate pathological entities, among them the below
described forms associated with EBV infection.
Nearly all of the EBV-positive lymphomas are
MUM1þ and CD10–, represent an aggressive clinical
phenotype, and are associated with a poor progno-
sis.77 The most important distinguishing features of
these lymphomas are presented in Table 2.EBVþ DLBCL of the Elderly
This neoplasm is classified in the group of not
otherwise specified (NOS) DLBCLs. The condition,
being a result of not fully understood alterations,
typically develops in individuals who are older than
50 years and show no signs of immune disorders.
The male to female ratio of patients with this form of
DLBCL is 1.4:1.78 According to current studies, EBVþ
DLBCL of the elderly accounts for 8%–10% of
DLBCLs diagnosed in Asian patients, which makes
it the most common subtype of EBV-associated
DLBCL. In contrast, the disease seems to be uncom-
mon in Western populations, which points to its
potential ethnic or geographic background.78,79
Usually, the malignancy is present in extranodal
locations, as an infiltrate of polymorphic, large cellsTable 2. Crucial Distinguishing Features of EBV-Ass
Type of
Lymphoma
Main Location Morph
EBVþ DLBCL of
the elderly
Lymph nodes; extranodal
locations
Plasmac
pleom
DLBCL associated
with chronic
inﬂammation
Extranodal: pleural cavity,
articular cavities, serous
membranes, skin
Variable
Primary effusion
lymphoma
Body cavities Immuno
anapl
Lymphomatoid
granulomatosis
Extranodal: lungs, skin,
brain, liver, kidneys
Pleomor
angio
Primary DLBCL of
central nervous
system
Extranodal: CNS Polymor
Plasmablastic
lymphoma
Extranodal: oral cavity,
alimentary tract
Immuno
plasmwith an inflammatory background. The Reed-Stern-
berg–like cells expressing CD20, CD79a, EBER, and
LMP-1, and lacking expression of CD15 antigen, can
be observed sometimes in the infiltrate.79
DLBCL Associated With Chronic Inﬂammation
This disease affects mostly older persons and is
associated with persistent (410 years) chronic
inflammation. The condition is primarily extranodal
and typically involves the pleural cavity. The vast
majority of the cases are associated with EBV
infection. The prototype of this lymphoma is
pyothorax-associated lymphoma (PAL). This condi-
tion, originally described in Japan, is diagnosed in
patients from other countries as well.80 The lym-
phoma presents as a massive infiltrate around the
lung, developing after many years of pyothorax
associated with the treatment of lung tuberculosis
with artificial pneumothorax. Other locations of
lymphomas representing this phenotype include
bones, articular cavities, and periarticular connective
tissue of patients with a long-year history of osteo-
myelitis and metal implants, or the skin of individu-
als with chronic phlebitis and venous ulcers.81 The
morphology of these lymphomas is similar as in the
case of NOS DLBCLs. They are usually CD20-,
CD79a-, and CD30þ, but they also may show plas-
macytic differentiation, with expression of CD138
and MUM1, and loss of B-cell marker expression. The
lymphoma cells usually express EBV-LMP1. How-
ever, they also may co-express the T-cell–specific
markers, which hinders their appropriate classifica-
tion. DLBCL associated with chronic inflammation isociated DLBCLs
ology Immunophenotype
ytoid,
orphic
CD45þ, CD20þ MUM1þ CD30þ, CD20,
CD79aþ, EBERþ, LMP-1þ, CD15-
CD45þ, CD20þ, CD30þ, MUM1þ,
sometimes CD138þ, CD20-, EBERþ,
LMP-1þ
blastic,
astic
CD20-, CD45þCD138þ, MUM1þPAX5-,
CD30þ, HLA-DRþ, EMAþ, Vs38cþ,
EBERþ, CD19-, CD20-, CD79a-,
immunoglobulin-
phic,
centric
CD45þ, CD20þ, MUM1þ, CD30þ/–,
CD79a–/þ, CD15, LMPþ/–, EBERþ
phic Bcl-6þ, Mum-1þ, sometimes CD10þ
blastic
ablastic
CD20-, CD45-, CD38þ, Vs38cþ,
CD45þCD138þ, IRF4/MUM1þPAX5-,
CD79aþ, sometimes EMAþ, CD30þ
E. Grywalska and J. Rolinski298an aggressive lymphoma. Furthermore, the cells of
this lymphoma show a number of cytogenetic
anomalies. The 5-year survival rate of patients with
PAL is approximately 20%–35% years.82
Primary Effusion Lymphoma
Primary effusion lymphoma (PEL) should be dis-
tinguished from DLBCL associated with chronic
inflammation. Effusion in one of the body cavities
(pleural, pericardial, or peritoneal cavity), without
lymph node enlargement and lymphadenopathy, is
the clinical characteristic of PEL. This condition is
diagnosed in HIV-positive persons, patients with
severe immune deficiency and EBV infection, and
in individuals with HHV-8 co-infection and transplant
patients.83 The PEL cells are large, anaplastic or with
plasmablastic characteristics. The lymphoma repre-
sents a CD45þ phenotype, and lacks the markers
specific for B lymphocytes (CD19, CD20, CD79a,
and immunoglobulins) and bcl-6. However, it
expresses a number of molecules, such as CD30,
HLA-DR, EMA, and other plasmacyte-associated
markers (CD38, Vs38c, CD138). The expression of
T-lymphocyte–specific markers is aberrant. The pres-
ence of EBER is detected in 70% of the cases.83
Prognosis is very poor, with a median survival of
6 months.70
Lymphomatoid Granulomatosis
This is a rare disease referred to as EBV-associated
angiocentric and angiodestructive lymphoprolifera-
tion.70,78 The incidence in men is twice as high as in
women; although the condition is typical for adults,
also pediatric cases were reported.70 Lymphomatoid
granulomatosis is characterized by the presence of a
polymorphic infiltrate composed of small T lympho-
cytes, histiocytes, plasmatocytes and a variable num-
ber of immunoblasts and HRS-like cells with CD20þ,
CD30þ/–, CD79a–/þ, CD15, LMPþ/–, EBERþ pheno-
type. These cells infiltrate and destroy blood vessels,
especially in the lungs, brain, kidneys, liver, and
skin.17 The cytological grade (grades I–III) is deter-
mined on the basis of large cell (EBVþ) numbers.
Primary DLBCL of the Central Nervous System
This entity includes all primary cerebral and
ocular lymphomas that rarely spread outside the
CNS or to the bone marrow. They typically recur
within the CNS as well; the systemic recurrence, if
present, quite frequently involves testicles or
breasts. CNS DLBCLs show a tendency to occur late
in the course of HIV infection and are associated
with EBV infection in virtually 100% of the cases.84
Large lymphoma cells can be accompanied by small
reactive lymphocytes, microglial cells, and activatedastrocytes; also necrotic foci may develop.85 The
phenotypic characteristics of these lymphomas cor-
respond to NOS DLBCL phenotype. Expression of
Bcl-6 and Mum-1 is observed in 60%–80% of EBVþ
CNS DLBCLs and in 90% of EBV– CNS DLBCLs.
Presence of the CD10 maker is detected in approx-
imately 10% of cases.86 Prognosis is poor; median
survival of patients with the EBVþ form ranges
between 2 and 12 months from diagnosis.87
Plasmablastic Lymphoma
This is a rare lymphoma, originally described on
oral and nasal mucosal membranes of HIVþ per-
sons.88 Nearly 100% of the cases turn out to be
associated with EBV infection.89 Plasmablastic lym-
phoma (PBLs) also can affect HIV– individuals with
immunosuppression after organ transplantation.90
Furthermore, they may develop in extranodal loca-
tions: in myeloma patients (as a manifestation of
plasmablastic transformation of myeloma cells) and
in (usually older) persons without documented
immune deficiency.91 The morphology of PBL
resembles those of plasmablastic or centroblastic
variants of DLBCLs, but the B-cell phenotype is
weakly manifested or lacking.78 In turn, the PBL
cells express CD138, CD38, Vs38c, and MUM1, and
frequently also CD79a, EMA, and CD30. PBL show
extremely high proliferation rates. They represent a
highly aggressive clinical phenotype.
EBV-Associated NK/T-Cell Lymphomas
Angioimmunoblastic T-Cell Lymphoma (AITL)
This type of lymphoma was distinguished from
the group of peripheral (extrathymic) T-cell lympho-
mas due to its different clinical, morphologic, and
immunogenetic characteristics. Usually, the disease
manifests between 57 and 68 years of age, and is
characterized by fever and other B-symptoms, lymph
node enlargement, hepatomegaly, splenomegaly,
and polyclonal hypergammaglobulinemia. The clin-
ical manifestation may raise suspicion of an auto-
immune condition.92 One third of the patients
present with skin lesions (usually purpura-like rash).
The clinical outcome is heterogeneous, from sponta-
neous remission to rapid progression with fatal
outcome. Morphologically, the condition presents
as a diffuse lymphoma with retained abnormal
follicles in the lymph node. Histological examination
reveals neoplastic cells with abundant, optically
clear cytoplasm, proliferating blood vessels, epithe-
lial histiocytes, plasmacytes, eosinophilic granulo-
cytes, and clusters of dendritic cells.93 The
neoplastic cells represent CD2þ, CD3þ, CD4þ,
CD10þ, CXCL-13þ, PD1þ, and sometimes also BCL-
6þ phenotypes.94 Immunoblasts frequently show the
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lent chromosomal abnormalities include trisomy of
chromosomes 3 and 5, and the presence of an extra
X chromosome; moreover, a somatic RHOA muta-
tion was recently detected.92 Administration of
corticosteroids and multidrug cytostatics chemother-
apy results in 50%–70% of complete remission rates;
nevertheless, 5-year survival rates in low- and
extremely high-risk patients do not exceed 44%
and 24%, respectively.93Extranodal NK/T-Cell Lymphoma, Nasal Type
(ENKTL, Nasal Type)
This is a rare lymphoma with EBV infection-
associated etiopathogenesis. The incidence of this
neoplasm varies depending on a geographic region;
it is highly prevalent among patients from Asia,
Mexico and South America.95 Men are affected more
often than women, with 2–3:1 male to female ratio,
and the mean age at diagnosis is 50 years.96 The
neoplasm develops as a result of malignant trans-
formation of NK cells that express CD2, CD56, and
TIA-1 and lack the rearrangement of the T-
lymphocyte antigen-receptor gene, CD3.70 The lym-
phoma cells express EBER.97 The disease can occur
in any extranodal location, frequently mimicking an
inflammatory process; the upper airways, especially
the nasal cavity, are among the most frequently
involved organs.98 Extranodal NK/T-cell lymphoma
(ENKTL) is characterized by a progressive and
destructive inflammatory-proliferative process, high
aggressiveness, and an angiocentric and angiodes-
tructive growth pattern.97 Depending on the therapy
implemented, 5-year survival rates range between
40% and 65%; chemoradiotherapy shows the most
satisfactory treatment outcomes.99Aggressive NK-Cell Leukemia/Lymphoma
This condition also is associated frequently with
EBV infection. Its clinical manifestation is dominated
by the presence of nonspecific B-symptoms, massive
hepatomegaly with liver dysfunction, and splenome-
galy.98 Median age at diagnosis is 40 years; the
condition is slightly more frequent in men than in
women.99 Most patients present with anemia and
thrombocytopenia. The NK cell count in peripheral
blood usually exceeds 10,000/mL. Neoplastic cells
also are present in bone marrow. The disease
represents a highly aggressive clinical phenotype:
most patients die within 2 months from diagnosis.
The phenotype of aggressive NK-cell leukemia/lym-
phoma (ANKL) leukemic cells is characterized by the
presence of CD2, CD56, and sometimes also CD16
antigens, and lacks the CD3 molecule. Although del
(6)(q21q25) is the most common cytogeneticabnormality, other clonal aberrations can be not
observed not infrequently in the ANKL cells.100
EBV-Positive T-Cell Lymphoproliferative
Disorders of Childhood
Hydroa Vacciniforme-Like Lymphoma
This rare EBV-positive lymphoma is mostly diag-
nosed in children and youth from Asia, Mexico, and
Latin America.101 The patients present with photo-
sensitivity and insect bite sensitivity. The spectrum
of skin lesions includes edema, blisters and scabbed
ulcerations that heal with scarring.102 Lymphaden-
opathy and hepatosplenomegaly are observed in 30%
and 10% of the cases, respectively.70,103 Histopatho-
logical examination reveals proliferation of small and
medium-sized lymphocytes in the epidermis and
dermis, with penetration of the subcutaneous tissue.
The infiltration is angiocentric. The cells are charac-
terized by the CD2þ, CD3þ, CD4þ, CD5þ, CD8þ,
TIA-1þ, GrBþ, CD56–, and L26– phenotypes. Further-
more, the expression of EBER can be detected using
in situ hybridization.101 Prognosis is poor, with 2-
year survival rates up to 43%.103 However, treatment
with IFN-alpha can yield a satisfactory therapeutic
outcome.101
Systemic EBV-Positive T-Cell Lymphoprolifera-
tive Disorders of Childhood
This disease represents a rare clonal proliferation
of EBV-infected T cells with an activated cytotoxic
phenotype. It occurs with increased frequency in
immunocompetent children and young adults,
appears to be more common in Asians and native
Americans, and is associated with rapid progression,
and high morbidity and mortality.104 It can develop
after primary EBV infection or be linked to chronic
active EBV infection (CAEBV). Despite the name, the
disease occurs not only in children but in adoles-
cents and young adults as well, with a median age at
diagnosis of approximately 20 years.105 The cellular
infiltrate is usually composed of small lymphocytes
that typically occupy the splenic and hepatic
sinuses, with significant hemophagocytosis.106 How-
ever, the cases with pleomorphic medium- or large-
sized lymphoid cells, irregular nuclei and frequent
mitoses have been described as well. The lymphoma
cells present with CD2þ, CD3þ, TIAþ, CD8þ (in the
case of acute EBV infection) or CD4þ (if the diseases
developed as a result of CAEBV), EBERþ, CD56–,
TIAþ phenotype.107
CONCLUSION
Although it has been 50 years since the first report
confirming the involvement of EBV in the etiology of
endemic BL was published,65 still the role of this
E. Grywalska and J. Rolinski300virus in the pathogenesis of other malignancies,
especially those of lymphoid origin, is the subject
of extensive research. The results are inconclusive,
as both the reports confirming and the reports
negating involvement of EBV in the etiology of
various conditions are being published. Also the
roles of both latent proteins and homologues of
human proteins are studied extensively with regards
to neoplastic transformation: signal transduction,
initiation of cell division, control of growth and
differentiation, cell cycle regulation, expression of
new surface receptors, and structural alterations of
adhesion molecules. The studies of protein expres-
sion will enable us to identify signaling pathways
that can be altered within a host’s cell. Identification
of a stage at which the disorders leading to cell
immortalization or proliferation occur is vital in the
context of finding efficient antineoplastic therapies,
especially against lymphomas.REFERENCES
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